439 related articles for article (PubMed ID: 37258233)
1. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD.
Yamada S; Nakano T
J Atheroscler Thromb; 2023 Aug; 30(8):835-850. PubMed ID: 37258233
[TBL] [Abstract][Full Text] [Related]
2. Mineral metabolism and cardiovascular disease in CKD.
Fujii H; Joki N
Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):53-63. PubMed ID: 28062938
[TBL] [Abstract][Full Text] [Related]
3. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications.
Kaur R; Singh R
Life Sci; 2022 Dec; 311(Pt B):121148. PubMed ID: 36336124
[TBL] [Abstract][Full Text] [Related]
5. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
[TBL] [Abstract][Full Text] [Related]
6. The Importance of Phosphate Control in Chronic Kidney Disease.
Tsuchiya K; Akihisa T
Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
8. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
Omata M; Fukagawa M; Kakuta T
Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
[TBL] [Abstract][Full Text] [Related]
9. Emerging cross-talks between chronic kidney disease-mineral and bone disorder (CKD-MBD) and malnutrition-inflammation complex syndrome (MICS) in patients receiving dialysis.
Yamada S; Tsuruya K; Kitazono T; Nakano T
Clin Exp Nephrol; 2022 Jul; 26(7):613-629. PubMed ID: 35353283
[TBL] [Abstract][Full Text] [Related]
10. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
Shalhoub V; Shatzen EM; Ward SC; Davis J; Stevens J; Bi V; Renshaw L; Hawkins N; Wang W; Chen C; Tsai MM; Cattley RC; Wronski TJ; Xia X; Li X; Henley C; Eschenberg M; Richards WG
J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).
Hruska KA; Choi ET; Memon I; Davis TK; Mathew S
Pediatr Nephrol; 2010 Apr; 25(4):769-78. PubMed ID: 19898875
[TBL] [Abstract][Full Text] [Related]
12. Osteo-renal regulation of systemic phosphate metabolism.
Razzaque MS
IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
[TBL] [Abstract][Full Text] [Related]
13. The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.
Hruska KA; Sugatani T; Agapova O; Fang Y
Bone; 2017 Jul; 100():80-86. PubMed ID: 28119179
[TBL] [Abstract][Full Text] [Related]
14. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
[TBL] [Abstract][Full Text] [Related]
15. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management.
Pazianas M; Miller PD
J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482
[TBL] [Abstract][Full Text] [Related]
16. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
[TBL] [Abstract][Full Text] [Related]
17. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
18. FGF23 Actions in CKD-MBD and other Organs During CKD.
Sun T; Yu X
Curr Med Chem; 2023; 30(7):841-856. PubMed ID: 35761503
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
[TBL] [Abstract][Full Text] [Related]
20. Association between CKD-MBD and mortality in older patients with advanced CKD-results from the EQUAL study.
Magagnoli L; Cozzolino M; Caskey FJ; Evans M; Torino C; Porto G; Szymczak M; Krajewska M; Drechsler C; Stenvinkel P; Pippias M; Dekker FW; de Rooij ENM; Wanner C; Chesnaye NC; Jager KJ;
Nephrol Dial Transplant; 2023 Oct; 38(11):2562-2575. PubMed ID: 37230954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
